Stanford’s March 2024 study shows electric field bioprinting improves muscle fiber alignment by 40%, advancing regenerative medicine for injuries and aging, with potential clinical applications ...
A new blood test based on p-tau217 biomarker can predict Alzheimer’s symptom onset in 3-4 years with high accuracy, offering early intervention opportunities. Recent studies validate a p-tau217 ...
New research reveals Ube2g1 upregulation in hematopoietic stem cells drives immune senescence via tyrosine phosphorylation, offering insights for reversing age-related decline, based on Haematologica ...
Partial OSK reprogramming rejuvenates engram neurons in aged mice, improving memory by over 50%, with recent studies enhancing safety and biotech firms advancing towards human trials. New research sho...
A new AI system, DeepRare, demonstrates superior accuracy in diagnosing rare diseases using real-time data and self-reflective reasoning, as detailed in a 2026 Nature study, with potential to reduce d...
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
The ARMOR clinical trial investigates FMT from young, active donors to older adults to enhance muscle, cognitive, and metabolic health, addressing gut dysbiosis for aging resilience. A groundbreaking ...
Recent studies reveal CAR-T cells with lecanemab antibodies reduce amyloid plaques in mice, highlighting a shift towards personalized cell-based therapies for Alzheimer’s treatment. New research...
Research shows muscularis macrophages in the gut trigger α-synuclein misfolding in Parkinson’s disease, spreading to the brain via immune pathways, with potential for early intervention through...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
